GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Amoy Diagnostics Co Ltd (SZSE:300685) » Definitions » Gross Profit

Amoy Diagnostics Co (SZSE:300685) Gross Profit : ¥910 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Amoy Diagnostics Co Gross Profit?

Amoy Diagnostics Co's gross profit for the three months ended in Mar. 2024 was ¥197 Mil. Amoy Diagnostics Co's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ¥910 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Amoy Diagnostics Co's gross profit for the three months ended in Mar. 2024 was ¥197 Mil. Amoy Diagnostics Co's Revenue for the three months ended in Mar. 2024 was ¥233 Mil. Therefore, Amoy Diagnostics Co's Gross Margin % for the quarter that ended in Mar. 2024 was 84.46%.

Amoy Diagnostics Co had a gross margin of 84.46% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 12 years, the highest Gross Margin % of Amoy Diagnostics Co was 94.19%. The lowest was 82.45%. And the median was 90.60%.

Warning Sign:

Amoy Diagnostics Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -2%.


Amoy Diagnostics Co Gross Profit Historical Data

The historical data trend for Amoy Diagnostics Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amoy Diagnostics Co Gross Profit Chart

Amoy Diagnostics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 522.65 633.45 773.76 694.37 876.21

Amoy Diagnostics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 163.68 219.87 208.01 284.65 197.03

Competitive Comparison of Amoy Diagnostics Co's Gross Profit

For the Diagnostics & Research subindustry, Amoy Diagnostics Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amoy Diagnostics Co's Gross Profit Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Amoy Diagnostics Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Amoy Diagnostics Co's Gross Profit falls into.



Amoy Diagnostics Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Amoy Diagnostics Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=1043.507 - 167.294
=876

Amoy Diagnostics Co's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=233.289 - 36.258
=197

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥910 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Amoy Diagnostics Co's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=197 / 233.289
=84.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Amoy Diagnostics Co  (SZSE:300685) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Amoy Diagnostics Co had a gross margin of 84.46% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Amoy Diagnostics Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Amoy Diagnostics Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Amoy Diagnostics Co (SZSE:300685) Business Description

Traded in Other Exchanges
N/A
Address
39 Dingshan Road, Haicang District, Xiamen, CHN, 361027
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Executives
Ruan Li Directors, executives
Zheng Hui Bin Directors, executives
Chen Ying Directors, executives
Luo Jie Min Executives
Zhu Guan Shan Directors, executives
Yang Shou Qian Securities Affairs Representative
Zhou Wen Gang Executives
Zhou Xue Lin Independent director
Hu Xu Bo Director

Amoy Diagnostics Co (SZSE:300685) Headlines

No Headlines